Harmony Biosciences Holdings, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological disorders, primarily focusing on innovative treatments to address unmet medical needs. Its core product portfolio centers on WAKIX (pitolisant), the first and only FDA-approved oral medication for excessive daytime sleepiness in adult patients with narcolepsy. The company also develops pipeline candidates such as EPX-100 (clemizole hydrochloride) for Dravet syndrome, EPX-200 (lorcaserin) targeting other rare neurological conditions, and CBS-104, a regenerative cellular therapy for refractory epilepsy. Harmony Biosciences markets these products primarily in the United States and pursues expansion through clinical development in other rare disease indications. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company strategically expanded by acquiring Epygenix Therapeutics in 2024, gaining late-stage epilepsy assets and enhancing its CNS rare disease pipeline. Recently, it announced positive results from a pivotal bioequivalence study for pitolisant’s gastro-resistant formulation, setting the stage for a New Drug Application submission in early 2026, and is advancing phase 3 clinical trials for EPX-100 in Dravet syndrome with topline data expected in 2026. Additionally, Harmony entered into a strategic financing agreement with Blackstone in 2024, securing up to $330 million to support its growth initiatives. The company actively presents clinical data at major scientific forums and continues developing multiple CNS programs targeting rare neurological disorders across the U.S. and beyond.
Company News
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLC
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Why Harmony Biosciences Stock Got Mashed on Monday
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?
Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Insider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock
Kumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement System